Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROXI-CATH
2023-508603-21-00Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of amrecibart and REGN7508 in venous thromboembolism (VTE) (4 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Incidence of confirmed venous thromboembolism and Incidence and severity of treatment-emergent adverse events. Started Aug 2024; status: completed.
02
Drugs
amrecibartREGN7508
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2023-508603-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508603-21-00.